HCM HUTCHMED (China) Limited
Price Chart
Executive Summary
HUTCHMED has initiated a Phase I/IIa clinical trial for HMPL-A580, its second Antibody-Targeted Therapy Conjugate (ATTC), in patients with advanced solid tumors in both China and the US. The first patient was dosed on March 4, 2026, marking a key step in the development of this first-in-class therapy targeting the PAM pathway and EGFR signaling.
Actionable Insight
Monitor upcoming preclinical data presentations and Phase I safety/dose escalation results, which could serve as catalysts. This trial expands HUTCHMED’s ATTC platform validation but is too early to impact near-term valuation.
Key Facts
- HUTCHMED initiated a Phase I/IIa trial for HMPL-A580, its second ATTC candidate, on March 4, 2026.
- The trial is ongoing in the US and China and is first-in-human, evaluating safety, pharmacokinetics, and preliminary efficacy.
- HMPL-A580 combines a novel PI3K/PIKK inhibitor payload with an anti-EGFR antibody to target EGFR-expressing solid tumors.
- Preclinical data suggest synergistic activity between PAM pathway inhibition and EGFR blockade.
- Trial details are available at clinicaltrials.gov under NCT07396584.
Financial Impact
No immediate financial impact; early-stage trial with potential long-term value if clinical success is achieved
Risk Factors
- High risk typical of early-phase clinical development; safety or tolerability issues could halt development.
- Limited near-term commercial visibility; multi-year timeline to potential approval, if successful.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249083 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 9, 2026
8w ago
|
Press Release
| $15.16 $13.43 | ▼ −11.41% | ▼ −18.98% | $10.63 (−29.88%) |
|
Mar 23, 2026
11w ago
|
Press Release
| $14.00 $14.87 | ▲ +6.21% | ▼ −1.21% | $10.63 (−24.07%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $13.85 $15.42 | ▲ +11.34% | ▲ +15.12% | $10.63 (−23.25%) |
|
Mar 4, 2026
13w ago
|
Press Release
| $13.65 $15.14 | ▲ +10.96% | ▲ +15.37% | $10.63 (−22.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access